Coronavirus vaccine could get emergency approval before critical testing is complete, FDA says

The head of the U.S. Food and Drug Administration says that coronavirus vaccines may be given emergency approval before rigorous clinical trials are complete, according to recent news reports.

Only a couple of coronavirus vaccine candidates in the U.S. have advanced to phase 3 clinical trials, which are the most critical tests needed to prove, in tens of thousands of people, that a vaccine is both safe and effective at preventing COVID-19. Typically, a vaccine must pass these advanced trials before given approval — but the pandemic has pushed vaccine development to unprecedented timescales.

“It is up to the sponsor [vaccine developer] to apply for authorization or approval, and we make an adjudication of their application,” Dr. Stephen Hahn, the FDA Commissioner told The Financial Times. “If they do that before the end of phase three, we may find that appropriate. We may find that inappropriate, we will make a determination.”

Related: Coronavirus live updates

Hahn said a safe way to roll out the vaccine prior to results from phase 3 trials, is to issue an emergency use authorization for only a select group of people, according to the Financial Times. “Our emergency use authorization is not the same as a full approval,” he told the Times.

Emergency use authorization is permission granted to unapproved products to be used in an emergency to diagnose, treat or prevent serious or life-threatening conditions, “when there are no adequate, approved and available alternatives,” according to the FDA. China and Russia have both given emergency approvals to coronavirus vaccines for a limited group of people prior to phase 3 results, according to the Times. 

But approving vaccines too soon can be risky, public health officials have warned.

Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, previously told Reuters that a vaccine should not receive an emergency use authorization before it’s shown to be effective. “One of the potential dangers if you prematurely let a vaccine out is that it would make it difficult, if not impossible, for the other vaccines to enroll people in their trial,” he said.

“To me, it’s absolutely paramount that you definitively show that a vaccine is safe and effective, both,” Fauci told Reuters. “We would hope that nothing interferes with the full demonstration that a vaccine is safe and effective.”

Last week, the FDA gave an emergency use authorization to plasma therapy, or antibody-rich plasma taken from recovered patients, to treat COVID-19, quickly reversing its announcement that the FDA wouldn’t issue an EUA until there was more data that the therapy works, Live Science previously reported. The authorization followed on the tail of President Donald Trump’s remarks that the FDA’s decision to wait for more data before giving an EUA to plasma therapy could be political, according to the report. 

Related Content

Hahn told the Times that the decision to give an EUA on vaccines wouldn’t be politically driven.

“We have a convergence of the COVID-19 pandemic with the political season, and we’re just going to have to get through that and stick to our core principles,” he told the Financial Times. “This is going to be a science, medicine, data decision. This is not going to be a political decision.”

In the U.S., just two candidate vaccines are in phase 3 trials: one made by Moderna and the other by Pfizer and BioNTech, according to a Live Science roundup of coronavirus vaccine candidates in clinical trials. But there are several others that are expected to start phase 3 trials in the coming weeks. 

Originally published on Live Science.

Read The Full Article At LiveScience. This content is provided by LiveScience.Com at public RSS feed. Please contact us if you have any questions.

Be the first to comment

Leave a Reply

Your email address will not be published.


*


This site uses Akismet to reduce spam. Learn how your comment data is processed.